Skip to content
Disclosery

ENAVATE SCIENCES GP, LLC

Follow

13F filer, CIK 1953107, New York, NY

ENAVATE SCIENCES GP, LLC reported $345,377,333 across 7 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001953107-26-000012

Period
2026-06-30
Reported value
$345M
Holdings
7
Top 10 weight
100%
New
0
Sold out
0

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CAMPreduced-765,379-$3.34M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001953107-26-000012, largest first. % of portfolio is the value over $345,377,333, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
SIONSIONNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: 2,478,030 shares; 2025Q2: 2,478,030 shares; 2025Q3: 2,478,030 shares; 2025Q4: 2,478,030 shares; 2026Q1: 2,478,030 shares; 2026Q2: 2,478,030 shares 2,478,030$109M31.56%0Timeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 3,761,359 shares; 2025Q1: 3,761,359 shares; 2025Q2: 3,761,359 shares; 2025Q3: 3,761,359 shares; 2025Q4: 3,919,159 shares; 2026Q1: 3,919,159 shares; 2026Q2: 3,919,159 shares 3,919,159$99.5M28.8%0Timeline
IMNMIMMUNOME INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 3,478,261 shares; 2025Q1: 4,768,583 shares; 2025Q2: 4,768,583 shares; 2025Q3: 4,768,583 shares; 2025Q4: 4,768,583 shares; 2026Q1: 3,613,799 shares; 2026Q2: 3,613,799 shares 3,613,799$76.6M22.17%0Timeline
BBOTBRIDGEBIO ONCOLOGY THERAPEUTQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,626,946 shares; 2025Q4: 2,626,946 shares; 2026Q1: 2,626,946 shares; 2026Q2: 2,626,946 shares 2,626,946$20M5.8%0Timeline
CMPXCOMPASS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 7,788,150 shares; 2025Q1: 7,788,150 shares; 2025Q2: 7,788,150 shares; 2025Q3: 7,788,150 shares; 2025Q4: 7,788,150 shares; 2026Q1: 7,788,150 shares; 2026Q2: 7,788,150 shares 7,788,150$17.1M4.94%0Timeline
UPBUPSTREAM BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 2,459,703 shares; 2025Q1: 2,459,703 shares; 2025Q2: 2,459,703 shares; 2025Q3: 2,459,703 shares; 2025Q4: 2,459,703 shares; 2026Q1: 2,459,703 shares; 2026Q2: 2,459,703 shares 2,459,703$17M4.93%0Timeline
CAMPCAMP4 THERAPEUTICS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 3,785,802 shares; 2025Q1: 3,785,802 shares; 2025Q2: 3,785,802 shares; 2025Q3: 3,785,802 shares; 2025Q4: 3,035,825 shares; 2026Q1: 2,190,920 shares; 2026Q2: 1,425,541 shares 1,425,541$6.23M1.8%-765,379Timeline

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001953107-26-000012 base2026-08-14acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001953107-26-000012 Quarter ended 2026-06-302026-08-14acceptance time not in the bulk data set
13F-HR 0001953107-26-000008 Quarter ended 2026-03-312026-05-15acceptance time not in the bulk data set
13F-HR 0001953107-26-000003 Quarter ended 2025-12-312026-02-17acceptance time not in the bulk data set
13F-HR 0001953107-25-000014 Quarter ended 2025-09-302025-11-14acceptance time not in the bulk data set
13F-HR 0001415889-25-021852 Quarter ended 2025-06-302025-08-14acceptance time not in the bulk data set
13F-HR 0001415889-25-013132 Quarter ended 2025-03-312025-05-15acceptance time not in the bulk data set
13F-HR 0001104659-25-014094 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set